Related Experiment Video

Updated: Aug 21, 2026

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions
10:26

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions

Published on: December 20, 2017

A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells

David Michod1, Jiang-Yan Yang, Jianhua Chen

  • 1Department of cellular biology and morphology, Lausanne University, Switzerland.

Oncogene
|October 7, 2004
PubMed

Insights

Researchers developed a peptide that enhances cancer cell death from genotoxins like cisplatin. This peptide selectively targets tumor cells, sparing normal cells, and offers a promising strategy for more effective cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Cancer therapy often uses genotoxins, but side effects on normal cells limit treatment efficacy.
  • Increasing treatment selectivity towards cancer cells is a major challenge in oncology.
  • Previous work showed a RasGAP caspase cleavage fragment sensitizes HeLa cells to cisplatin.

Purpose of the Study:

  • To investigate if the RasGAP fragment enhances cancer cell death induced by other genotoxins.
  • To identify a minimal sequence within the fragment responsible for genotoxin sensitization.
  • To evaluate the efficacy and specificity of a peptide derived from this sequence in combination with genotoxins.

Main Methods:

  • Treatment of cancer and normal cells with genotoxins (cisplatin, adriamycin, mitoxantrone) alone and in combination with the RasGAP fragment or derived peptide.
  • Identification of a minimal sensitizing sequence within the RasGAP fragment.
  • Fusion of the identified peptide with the TAT cell permeation sequence.
  • Analysis of apoptosis induction in tumor and normal cells.
  • Assessment of NFkappaB activity and JNK/p38 MAPK pathway activation.

Main Results:

  • The RasGAP fragment enhanced apoptosis induced by adriamycin and mitoxantrone, in addition to cisplatin.
  • A short peptide sequence derived from the fragment retained the genotoxin-sensitization property.
  • The TAT-fused peptide selectively sensitized various tumor cells, but not normal cells, to genotoxin-induced apoptosis.
  • The sensitization mechanism did not involve modulation of NFkappaB or activation of JNK and p38 MAPK pathways.

Conclusions:

  • Peptides derived from pro-apoptotic caspase substrates can enhance the efficacy of existing genotoxic anticancer drugs.
  • This approach offers a strategy to selectively kill cancer cells while sparing normal tissues, potentially reducing side effects.
  • The TAT-fused peptide represents a promising tool for improving cancer therapy selectivity and effectiveness.

More Related Videos

Measuring RAN Peptide Toxicity in C. elegans10:49

Measuring RAN Peptide Toxicity in C. elegans

Published on: April 30, 2020

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.